Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,595.00
Bid: 1,594.00
Ask: 1,594.50
Change: -13.50 (-0.84%)
Spread: 0.50 (0.031%)
Open: 1,604.50
High: 1,609.00
Low: 1,586.50
Prev. Close: 1,608.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of GSK 2019 Form 20-F

9 Mar 2020 07:00

RNS Number : 3525F
GlaxoSmithKline PLC
09 March 2020
 

 

GlaxoSmithKline plcAnnual Report 2019 on Form 20-F

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 06 March 2020 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2019. GSK's 2019 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk.

A hard copy version of the GSK 2019 Annual Report, together with the Notice of Annual General Meeting will be available on or about 23 March 2020.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2020, free of charge, by either:

(i) writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii) writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 800 990 1135 (US toll free) or +1 651 453 2128 (outside the US); or

(iii) contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

Victoria WhyteCompany Secretary06 March 2020

 

Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2019.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKABDDBKBONK
Date   Source Headline
22nd Feb 20243:30 pmRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSViiV LAI superior to orals in adherence-challenged
20th Feb 20249:01 amRNSJulie Brown - External Appointment
19th Feb 20243:30 pmRNSDirector/PDMR Shareholding
15th Feb 20243:32 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSGSK completes acquisition of Aiolos Bio
13th Feb 20244:45 pmRNSDirector/PDMR Shareholding - Replacement
13th Feb 20243:40 pmRNSDirector/PDMR Shareholding
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
13th Feb 20243:30 pmRNSDirector/PDMR Shareholding
6th Feb 20247:10 amRNSFDA accepts Arexvy filing for adults 50-59 at risk
6th Feb 20247:05 amRNSShingrix 18+ at risk China filing review accepted
6th Feb 20247:00 amRNSGSK presents positive DREAMM-7 phase III data
1st Feb 20243:30 pmRNSDirector/PDMR Shareholding
1st Feb 20243:00 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
31st Jan 20247:00 amRNSFinal Results
29th Jan 20247:05 amRNSEMA accepts Arexvy filing for adults 50-59 at risk
29th Jan 20247:00 amRNSEuropean Commission authorises Omjjara in the EU
19th Jan 20243:30 pmRNSDirector/PDMR Shareholding
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20243:30 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th Jan 20244:40 pmRNSGSK announces intention to sell shares in Haleon
16th Jan 20243:30 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSNucala approved in China for use in severe asthma
9th Jan 20247:00 amRNSGSK enters agreement to acquire Aiolos Bio
2nd Jan 20243:00 pmRNSTotal Voting Rights
21st Dec 20233:30 pmRNSDirector/PDMR Shareholding
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
18th Dec 20237:00 amRNSJemperli plus Zejula Trial Meets Endpoint
13th Dec 20233:30 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSJapan accepts Arexvy filing for at risk adults
11th Dec 20237:00 amRNSJemperli plus chemotherapy EU authorisation
4th Dec 20233:02 pmRNSGSK publishes provisional 2024 dividend dates
1st Dec 20233:00 pmRNSTotal Voting Rights
30th Nov 20239:00 amRNSBlock Listing Application
29th Nov 20233:23 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSGSK announces positive DREAMM-7 headline results
21st Nov 20233:30 pmRNSDirector/PDMR Shareholding
15th Nov 20233:00 pmRNSBlock listing Interim Review
13th Nov 20233:30 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSGSK receives positive CHMP opinion for momelotinib
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNS3rd Quarter Results
30th Oct 20237:00 amRNSJemperli trial meets overall survival endpoint
26th Oct 20237:00 amRNSNMPA approves Vocabria+Rekambys in China
25th Oct 20233:30 pmRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSNew data for Arexvy, GSK’s RSV vaccine
20th Oct 20233:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.